Biosimilar rhG-CSFs: how similar are they?

First experience of autologous peripheral blood stem cell mobilization with biosimilar granulocyte colony- stimulating factor

(2011) François Lefrère et al.   ADVANCES IN THERAPY

Concerns about the use of biosimilar granulocyte colony-stimulating factors for the mobilization of stem cells in normal donors: position of the World Marrow Donor Association

(2011) B. E. Shaw et al.   HAEMATOLOGICA

Bioequivalence of two recombinant granulocyte colony-stimulating factor products after subcutaneous injection in healthy volunteers

(2011) H. Lubenau et al.   INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS

Worldwide experience with biosimilar development

(2011) Mark McCamish et al.   mAbs

The $640 Billion Question — Why Does Cost-Effective Care Diffuse So Slowly?

(2011) Victor R. Fuchs et al.   NEW ENGLAND JOURNAL OF MEDICINE

Qu’est-ce qu’un biosimilaire ? Jusqu’où va la similarité ?

(2011) P. Gravel et al.   Oncologie

Biosimilar epoetins and other “follow-on” biologics: Update on the European experiences

(2010) Wolfgang Jelkmann   AMERICAN JOURNAL OF HEMATOLOGY

Comparison of the pharmacodynamic profiles of a biosimilar filgrastim and Amgen filgrastim: results from a randomized, phase I trial

(2010) Cornelius F. Waller et al.   ANNALS OF HEMATOLOGY

Pharmacokinetic profiles of a biosimilar filgrastim and Amgen filgrastim: results from a randomized, phase I trial

(2010) Cornelius F. Waller et al.   ANNALS OF HEMATOLOGY

Physicochemical and Biologic Comparability of a Biosimilar Granulocyte Colony-Stimulating Factor with Its Reference Product

(2010) Fritz Sörgel et al.   BIODRUGS

Comparison of the physicochemical properties of a biosimilar filgrastim with those of reference filgrastim

(2010) A. Skrlin et al.   BIOLOGICALS

Addressing the health technology assessment of biosimilar pharmaceuticals

(2010) Alan Stewart et al.   CURRENT MEDICAL RESEARCH AND OPINION

2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours

(2010) M.S. Aapro et al.   EUROPEAN JOURNAL OF CANCER

Biosimilar agents in oncology/haematology: from approval to practice

(2010) Dietger Niederwieser et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

A Phase III Randomized Equivalence Study of Biosimilar Filgrastim versus Amgen Filgrastim in Patients Receiving Myelosuppressive Chemotherapy for Breast Cancer

(2010) Cornelius F. Waller et al.   Oncology Research and Treatment

Development of a new G-CSF product based on biosimilarity assessment

(2009) P. Gascon et al.   ANNALS OF ONCOLOGY

Pharmacokinetic and Pharmacodynamic Profile of New Biosimilar Filgrastim XM02 Equivalent to Marketed Filgrastim Neupogen®

(2009) Heinz Lubenau et al.   BIODRUGS

The EBMT activity survey 2007 with focus on allogeneic HSCT for AML and novel cellular therapies

(2009) A Gratwohl et al.   BONE MARROW TRANSPLANTATION

XM02, the First Biosimilar G-CSF, is Safe and Effective in Reducing the Duration of Severe Neutropenia and Incidence of Febrile Neutropenia in Patients with Small Cell or Non-small Cell Lung Cancer Receiving Platinum-Based Chemotherapy

(2009) Ulrich Gatzemeier et al.   Journal of Thoracic Oncology

XM02, the first granulocyte colony-stimulating factor biosimilar, is safe and effective in reducing the duration of severe neutropenia and incidence of febrile neutropenia in patients with non-Hodgkin lymphoma receiving chemotherapy

(2009) A. Engert et al.   LEUKEMIA & LYMPHOMA

XM02 is superior to placebo and equivalent to Neupogen™ in reducing the duration of severe neutropenia and the incidence of febrile neutropenia in cycle 1 in breast cancer patients receiving docetaxel/doxorubicin chemotherapy

(2008) A del Giglio et al.   BMC CANCER